Unknown

Dataset Information

0

Compstatin: a complement inhibitor on its way to clinical application.


ABSTRACT: Therapeutic modulation of the human complement system is considered a promising approach for treating a number of pathological conditions. Owing to its central position in the cascade, component C3 is a particularly attractive target for complement-specific drugs. Compstatin, a cyclic tridecapeptide, which was originally discovered from phage-display libraries, is a highly potent and selective C3 inhibitor that demonstrated clinical potential in a series of experimental models. A combination of chemical, biophysical, and computational approaches allowed a remarkable optimization of its binding affinity towards C3 and its inhibitory potency. With the recent announcement of clinical trials with a compstatin analog for the treatment of age-related macular degeneration, another important milestone has been reached on its way to a drug. Furthermore, the release of a co-crystal structure of compstatin with C3c allows a detailed insight into the binding mode and paves the way to the rational design of peptides and mimetics with improved activity. Considering the new incentives and the promising pre-clinical results, compstatin seems to be well equipped for the challenges on its way to a clinical therapeutic.

SUBMITTER: Ricklin D 

PROVIDER: S-EPMC2700864 | biostudies-literature | 2008

REPOSITORIES: biostudies-literature

altmetric image

Publications

Compstatin: a complement inhibitor on its way to clinical application.

Ricklin Daniel D   Lambris John D JD  

Advances in experimental medicine and biology 20080101


Therapeutic modulation of the human complement system is considered a promising approach for treating a number of pathological conditions. Owing to its central position in the cascade, component C3 is a particularly attractive target for complement-specific drugs. Compstatin, a cyclic tridecapeptide, which was originally discovered from phage-display libraries, is a highly potent and selective C3 inhibitor that demonstrated clinical potential in a series of experimental models. A combination of  ...[more]

Similar Datasets

| S-EPMC3518557 | biostudies-literature
| S-EPMC2760637 | biostudies-literature
| S-EPMC6092248 | biostudies-literature
| S-EPMC3137721 | biostudies-literature
| S-EPMC4380746 | biostudies-literature
| S-EPMC3138065 | biostudies-literature
| S-EPMC3014449 | biostudies-literature
| S-EPMC3095715 | biostudies-literature
| S-EPMC4177305 | biostudies-literature
| S-EPMC1995432 | biostudies-literature